AtriCure Reports Third Quarter 2026 Financial Results

What happened

AtriCure reported third-quarter 2026 worldwide revenue of $154.5 million, up 15.0% from the same quarter in 2025, or 15.1% on a constant-currency basis. U.S. revenue was $128.0 million, up $18.7 million, or 17.1%. The company attributed U.S. growth to sales of three named device groups.

Confirmed

Global impact / market context

Revenue growth can support AtriCure’s ability to fund operations and invest in its products, while the reported decline in minimally invasive ablation sales points to uneven performance across its offerings. The figures describe sales, not overall profit or cash available.

Analyst inference

The article reports growth in U.S. sales alongside a decline in minimally invasive ablation sales, indicating different trends across product areas. It gives no company-wide profit figures, outlook, or share-price response, so it does not establish whether growth improved overall returns.

Analyst inference

What to watch

1. Future quarterly reports could show whether sales of the cryoSPHERE MAX probe, EnCompass clamp, and AtriClip devices continue to support U.S. revenue growth. Analyst inference
2. Track whether minimally invasive ablation sales continue to decline; the article says this happened during the quarter but does not provide the amount of the decline. Confirmed
3. AtriCure’s CEO cited progress in the BoxX-NoAF clinical trial; future updates could clarify whether that progress leads to a commercial opportunity. Analyst inference

Evidence

• Original source link unavailable